What is the brand name of fluticasone propionate with salmeterol xinafoate?

Combination inhalers utilize a corticosteroid and a long-acting beta-2 agonist (LABA) to manage chronic respiratory diseases. The steroid reduces airway inflammation, while the LABA provides prolonged bronchodilation. These medications are indicated for maintenance therapy in asthma and COPD to prevent exacerbations. They are not intended for use as rescue medications during acute bronchospasm. Rationale: A. Symbicort is the brand name for the combination of budesonide and formoterol fumarate. Budesonide is a potent glucocorticoid, while formoterol is a LABA with a rapid onset. It is used for maintenance and, in some protocols, as a reliever, but it lacks fluticasone and salmeterol. B. Advair is the correct brand name for the fixed-dose combination of fluticasone propionate and salmeterol xinafoate. Fluticasone provides local anti-inflammatory action by inhibiting multiple cell types, while salmeterol provides bronchodilation for at least 12 hours. This combination is a cornerstone in managing moderate-to-severe persistent asthma. C. Proair is a brand name for albuterol sulfate, which is a short-acting beta-2 agonist (SABA). It is used strictly as a rescue inhaler for the immediate relief of acute asthma symptoms or exercise-induced bronchospasm. It does not contain a corticosteroid and is not a combination product. D. Combivent is a brand name for the combination of albuterol and ipratropium bromide. Ipratropium is a short-acting muscarinic antagonist (SAMA) that provides anticholinergic bronchodilation. This product is typically used in the management of COPD rather than as a maintenance therapy for chronic asthma.